within Pharmacolibrary.Drugs.ATC.G;

model G03FB08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.28,
    Cl             = 0.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.056,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Combination drug containing dydrogesterone (a synthetic progestogen) and estrogen (such as estradiol or estradiol valerate) used for hormone replacement therapy in postmenopausal women or for regulating menstrual cycles. The drug is approved in several countries for menopausal symptoms and prevention of endometrial hyperplasia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not directly reported in peer-reviewed literature for the fixed combination of dydrogesterone and estrogen (ATC G03FB08) in a population. Approximate values are estimated from monotherapy pharmacokinetic data in healthy adult women.</p><h4>References</h4><ol><li><p>Neumann, K, et al., &amp; Griesinger, G (2022). Dydrogesterone and 20α-dihydrodydrogesterone plasma levels on day of embryo transfer and clinical outcome in an anovulatory programmed frozen-thawed embryo transfer cycle: a prospective cohort study. <i>Human reproduction (Oxford, England)</i> 37(6) 1183–1193. DOI:<a href=&quot;https://doi.org/10.1093/humrep/deac045&quot;>10.1093/humrep/deac045</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35323905/&quot;>https://pubmed.ncbi.nlm.nih.gov/35323905</a></p></li><li><p>Campagnoli, C, et al., &amp; Peris, C (2007). Differential effects of various progestogens on metabolic risk factors for breast cancer. <i>Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology</i> 23 Suppl 1 22–31. DOI:<a href=&quot;https://doi.org/10.1080/09513590701585037&quot;>10.1080/09513590701585037</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17943536/&quot;>https://pubmed.ncbi.nlm.nih.gov/17943536</a></p></li><li><p>Mattsson, LA, et al., &amp; Gangar, K (2000). Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. <i>American journal of obstetrics and gynecology</i> 182(3) 545–552. DOI:<a href=&quot;https://doi.org/10.1067/mob.2000.104843&quot;>10.1067/mob.2000.104843</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10739506/&quot;>https://pubmed.ncbi.nlm.nih.gov/10739506</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03FB08;
